Pancreatic neuroendocrine tumors: A case-based evidence review

Figure 1 Management of pancreatic neuroendocrine tumors, according to functional status, adapted from European neuroendocrine tumor society 2023[33,34]. SSR: Somatostatin receptor; SSA: Somatostatin analog; PRRT: Peptide receptor radionuclide therapy.

Figure 2 Initial CT-TAP confirmed 10 cm × 9. 5 cm 1° mass in the pancreatic tail, extending diffusely into the pancreatic body. A and B: Evidence of metastasis – 15 cm necrotic mass in segment 8 of the liver (B); C: Increased Octreotide uptake is shown on the OctreoScan, confirming the presence of somatostatin receptor positivity.

Figure 3 The smallest 1° tumor size 20 months post-initial treatment with Everolimus and somatostatin analogue therapy.

Figure 4 48 months post-treatment showing disease progression (increase in 1° tumor size and secondary hepatic metastasis and nodal disease). A and B: Increased size in secondary hepatic mass (12.3 cm × 9.2 cm) at 49 months.